stockrowZai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow ZLAB
Alert me
Zai Lab Limited Unsponsored ADR (ZLAB) Revenue
Zai Lab Limited Unsponsored ADR's revenue for fiscal 2025 was $460.2M, up 15.3% from $399.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $441.7M. Over the past ten years it has ranged from $129.0K (fiscal 2018) to $460.2M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 7 consecutive fiscal years. Zai Lab Limited Unsponsored ADR ranks 43rd of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $460.2M | 15.33% |
| FY2024 | $399.0M | 49.59% |
| FY2023 | $266.7M | 24.03% |
| FY2022 | $215.0M | 49.01% |
| FY2021 | $144.3M | 194.77% |
| FY2020 | $49.0M | 277.04% |
| FY2019 | $13.0M | 9,965.89% |
| FY2018 | $129.0K | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $108.2M | 1.78% |
| Jun 2026 | $106.3M | 6.73% |
| Mar 2026 | $99.6M | (21.93%) |
| Dec 2025 | $127.6M | 9.91% |
| 27 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ADMA ADMA Biologics Inc compare | $519.2M |
| ZLAB Zai Lab Limited Unsponsored ADR | $441.7M |
| XNCR Xencor, Inc. compare | $105.0M |
| RCUS Arcus Biosciences, Inc. compare | $100.0M |
| RXRX Recursion Pharmaceuticals, Inc. compare | $68.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $25.9M |
| CLDX Celldex Therapeutics, Inc. compare | $887.0K |
| PHVS Pharvaris N.V. compare | — |
| MBX MBX Biosciences, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ZLAB
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement